PMID- 38484010
OWN - NLM
STAT- MEDLINE
DCOM- 20240327
LR  - 20240328
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Print)
IS  - 1935-2727 (Linking)
VI  - 18
IP  - 3
DP  - 2024 Mar
TI  - Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin 
      (IVIG).
PG  - e0012035
LID - 10.1371/journal.pntd.0012035 [doi]
LID - e0012035
AB  - BACKGROUND: Babesiosis is a worldwide emerging protozoan infection that is 
      associated with a spectrum of disease severity from asymptomatic infection to 
      severe organ damage and death. While effective treatment strategies are 
      available, some immunocompromised patients experience severe acute and 
      prolonged/relapsing illness due in part to an impaired host antibody response. 
      Intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in some 
      immunocompromised babesiosis patients, but its therapeutic effect is uncertain. 
      We evaluated the presence of Babesia microti antibodies in commercial samples of 
      IVIG. METHODS/PRINCIPLE FINDINGS: The presence of B. microti antibodies in 
      commercial samples of IVIG were tested using an immunofluorescence assay. A 
      subset of samples was then tested for B. microti antibodies using an enzyme 
      linked immunosorbent assay. Out of 57 commercial IVIG samples tested using IFA, 
      and 52 samples tested using ELISA, none were positive for B. microti antibodies. 
      CONCLUSIONS: Commercially available IVIG may not be of therapeutic benefit for 
      babesiosis patients. Additional sampling of IVIG for B. microti antibody and a 
      clinical trial of babesiosis patients given IVIG compared with controls would 
      provide further insight into the use of IVIG for the treatment of babesiosis.
CI  - Copyright: This is an open access article, free of all copyright, and may be 
      freely reproduced, distributed, transmitted, modified, built upon, or otherwise 
      used by anyone for any lawful purpose. The work is made available under the 
      Creative Commons CC0 public domain dedication.
FAU - Kostka, Julia
AU  - Kostka J
AUID- ORCID: 0000-0002-8347-4900
AD  - Infectious Disease, UConn Health, Farmington, Connecticut, United States of 
      America.
FAU - Maharjan, Anu S
AU  - Maharjan AS
AD  - Pathology and Laboratory Medicine, UConn Health, Farmington, Connecticut, United 
      States of America.
FAU - Kumar, Sanjai
AU  - Kumar S
AD  - Food and Drug Administration, Silver Spring, Maryland, United States of America.
FAU - Hackenyos, Douglas
AU  - Hackenyos D
AD  - Pharmacy, UConn Health, Farmington, Connecticut, United States of America.
FAU - Krause, Peter J
AU  - Krause PJ
AD  - Yale School of Public Health and Yale School of Medicine, New Haven, Connecticut, 
      United States of America.
FAU - Dieckhaus, Kevin
AU  - Dieckhaus K
AD  - Infectious Disease, UConn Health, Farmington, Connecticut, United States of 
      America.
LA  - eng
PT  - Journal Article
DEP - 20240314
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Antibodies, Protozoan)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Babesiosis/drug therapy
MH  - *Babesia microti
MH  - Antibodies, Protozoan
MH  - Enzyme-Linked Immunosorbent Assay
PMC - PMC10965045
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/03/14 18:42
MHDA- 2024/03/27 06:43
PMCR- 2024/03/14
CRDT- 2024/03/14 13:54
PHST- 2023/09/28 00:00 [received]
PHST- 2024/02/28 00:00 [accepted]
PHST- 2024/03/26 00:00 [revised]
PHST- 2024/03/27 06:43 [medline]
PHST- 2024/03/14 18:42 [pubmed]
PHST- 2024/03/14 13:54 [entrez]
PHST- 2024/03/14 00:00 [pmc-release]
AID - PNTD-D-23-01226 [pii]
AID - 10.1371/journal.pntd.0012035 [doi]
PST - epublish
SO  - PLoS Negl Trop Dis. 2024 Mar 14;18(3):e0012035. doi: 
      10.1371/journal.pntd.0012035. eCollection 2024 Mar.